Author: Editor

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer at ASCO GU 2016

Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016

Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical trial of ibrutinib vs chlorambucil in chronic lymphocytic leukemia (CLL) patients over the age of 65. Progression free survival (PFS) and overall survival (OS) were increased in the ibrutinib arm, demonstrating the superior efficacy of this drug over chlorambucil.

Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic leukemia (CLL), considering the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting.

Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).

Thomas J Kipps, MD from the University of California, San Diego, CA, provides an overview of the clinical trial RESONATE-2 comparing ibrutinib with chlorambucil in chronic lymphocytic leukemia (CLL) patients not suitable to receive standard chemotehrapy. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, that targets B-cells and causes them to leave the lymph nodes and bone marrow. This drug has been shown to be effective in the treatment of CLL and therefore it has been approved in relapsed disease as a single-agent. Patients in the ibrutinib arm had a longer progression free survival (PFS), and survival advantage over chlorambucil.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib. Prof. Dyer also discusses

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent sucesses of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.

Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting held in Orlando, FL. Dr Eichhorst gives an overview of the Phase III clinical trial comparing chlorambucil with ibrutinib as front-line therapies, and an overview of the Phase II clinical trial of venetoclax in chronic lymphocytic leukaemia (CLL) patients with 17p deletion.

At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of new combination therapies involving hypomethylating agents. Dr Daver focuses on the following combinations: decitabine and vosarocin; decitabine and venetoclax (ABT-199); cytarabine and SGN-CD33A a CD33a monoclonal antibody .

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer at ASCO 2016.

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer at ASCO GU 2016.

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer at ASCO GU 2016

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels at ASCO GU 2016

Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses Genetic Testing in Prostate Cancer at ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better results from ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular targets in CRPC at ASCO GU 2016

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses new recently discovered novel targets for CCRPC at ASCO GU 2016 in San Francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved agents such as abiraterone and enzalutamide at ASCO GU 2016 in San francisco.

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target molecular abnormalities in CRPC at ASCO GU 2016 in San Francisco.

Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the new data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on BGB-3111, a second generation Bruton’s tyrosine kinase (BTK) inhibitor. The data presented were obtained from a Phase I clinical trial, where the drug was well tolerated and demonstrated a good safety profile.

Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. The session outlines current epidemiological and behavioural evidence on the relationship between different lifestyle choices and the development of cancer. The session hosted talks by Paolo Boffetta, Peter Anderson and Martin Wiseman, and focused on diet, exercise and alcohol consumption.

Alan Burnett, MD from Cardiff University, Cardiff, UK discusses the new technology developments in the field of acute myeloid leukemia (AML), at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. He primarily discusses the use of genomic testing to provide a more accurate prognosis with conventional treatment, and the development of companion diagnostics (i.e. gene signatures that can help predict a response to a particular treatment). Other technologies discussed are the improvements on flow cytometry and its use in disease monitoring, in particular, we can now have a closer look at minimal residual disease. On the…

Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.

What is CLL? How and where does it start? CLL experts Dr. Nicole Lamanna of Columbia University Medical Center and Dr. Michael Keating of MD Anderson Cancer Center answer these questions, offering a clear and basic definition. Listen for Dr. Keating to share his insight about a possible future CLL vaccine. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our Ask the Expert series, CLL expert Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL question: Do inhibitor treatments have to be a lifelong medicine? Listen as Dr. Keating describes his personal disinclination for what he refers to as just controlling the disease and how he anticipates immunotherapy strategies being used to eventually eradicate CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating of MD Anderson Cancer Center answers the question: Does CLL return more aggressively after relapse than it was initially? Listen as Dr. Keating explores the tendencies of recurring CLL, including WBC doubling time and indolence. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco

Dr. Toni Choueiri, MD of Dana Farber gives an ASCO GU 2016 Update on Clear Cell and non-Clear Cell Renal Carcinomas from San Francisco.

Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN Solid Tumor phase Ib trial at ASCO GU 2016.

Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic advanced setting to earlier disease states in urothelial cancers. ASCO GU 2016 in San Francisco

Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. at ASCO GU 2016 in San Francisco.

Dr. Nima Sharifi, MD of Cleveland Clinic comments on how investigators are now looking to use new therapies earlier within prostate cancer disease states which may be more effective from ASCO GU 2016.

Dr. Nima Sharifi, MD at Cleveland Clinic gives an overview of his presentation Androgen Receptor New Ways of Targeting the Old Target at ASCO Gu 2016 in San Francisco

Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC at ASCO GU 2016 in San francisco

Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer at ASCO GU 2016 in San Francisco.

Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect current treatment paradigms for advanced prostate cancer at ASCO GU 2016 in San Francisco.

Nima Sharifi, MD of Cleveland Clinic discusses the new Androgen Receptor Signaling and the new targets and agents for advanced prostate cancer at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD at Cleveland Clinic discusses the correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC) at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone prednisone at ASCO GU 2016 in San Francisco.

Dr. Petros Grivas, MD of Cleveland Clinic discusses The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC) from ASCO GU 2016.

Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors in RCC at ASCO GU 2016

“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukaemia (CLL) cells and the common side-effects experienced by these drugs. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.”

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia (CLL), as a single-agent and in combination with other therapies. Peter Hillmen discusses two studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting. These clinical trials study the use of venetoclax with rituximab and venetoclax with obinutuzumab.

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of ibrutinib vs. chlorambucil as front-line therapy, in patients unfit for fludarabine, cyclophosphamide, rituximab (FCR) therapy. The Phase III results presented at the American Society of Hematology (ASH) 2015 Annual Meeting, show that 98% of patients in the ibrutinib arm have a progression free survival period longer than 2 years.

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase Ib study of venetoclax (ABT-199) and obinutuzumab, an anti-CD20 antibody, in relapsed/refractory or previously untreated chronic lymphocytic leukaemia (CLL). The preliminary data show patients achieving minimum residual disease (MRD) states with no toxicity.

Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 96% of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.

Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.

Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.

Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that had no post-trial access to ibrutinib, or those who moved to a comparator. The insights from this study help to inform decisions regarding sequential and salvage treatments.

Dr. Walter Stadler of the University of Chicago discusses how Checkpoint inhibitors iwill mpact outcomes for advanced RCC

Dr. Walter Stadler discusses his experience with FDA approved Nivolumab and PD-1 and PD-L1 inhibitors in RCC

Patient Power founder Andrew Schorr along with patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting sit down with Dr. Jennifer Cultrera to discuss the progress in treating follicular lymphomas. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How far have we progressed in the field of CLL research? Patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) meeting, visited with leading CLL expert Dr. Richard Furman to hear his perspective on news from the conference. Listen as Dr. Furman gives a rundown of last years novel agents and todays best possibility for deep remission. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says, Yes! On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew Schorr visits with Dr. Sweetenham to discuss emerging agents and monitoring strategies for patients with Hodgkin lymphoma. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Are clinical trials still valid as a means for treatment? On location at the 2015 American Society of Hematology (ASH), Medical Correspondent, Carol Preston, speaks with myeloma expert Dr. Sagar Lonial, Chief Medical Officer at Winship Cancer Institute of Emory University, about the rapidly changing therapies for multiple myeloma patients. Listen as Dr. Lonial makes a strong statement for clinical trials as the catalyst for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma.

Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a second-generation BTK inhibitor, with CLL expert Dr. Kathryn Kolibaba. Dr. Kolibaba describes this new molecules function including its potential for decreased side effects and her hopes for the future. Never, exclaims Dr. Kolibaba, have we had a better menu of options. Never have we had hope like we do now for a cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our coverage of the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center joined Patient Power to discuss social media and hematology, focusing on a well-attended session from the meeting. Dr. Pemmaraju expands on the benefits of using social media to educate patients as well as potential issues with this form of communication. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Lymphoma expert Dr. Jeff Sharman, on location at 2015 American Society of Hematology (ASH) meeting, reviews the advancement of follicular lymphomas (non-Hodgkin lymphomas) as they rapidly progress towards becoming a chronic condition. Watch as Dr. Sharman extends hope to patients through use and understanding of clinical trials. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Hematology (ASH) conference, patient advocate Carol Preston and Dr. Christopher Yasenchak, from US Oncology Research, discuss encouraging news for Hodgkin lymphoma patients who are over 60 years old. Dr. Yasenchak explains why 50 percent of older patients cannot tolerate current potent chemo side effects and the exciting new combination treatments in pre-clinical trial that offer, as Dr. Yasenchak says a game-changing opportunity. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Endocrine therapy may cause many bothersome side effects, often affecting a patients compliance. Dr Naughton suggests BCI as a tool to objectively help patients understand their likelihood of benefit and help encourage them to continue therapy, if appropriate. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Is there current research for the 20 percent of CML (Chronic Myelogenous Leukemia) patients who are resistant to imatinib mesylate (Gleevec)? CML expert Dr. Kathryn Kolibaba answers with an emphatic Yes!. Patient advocate Carol Preston speaks with Dr. Kolibaba as they discuss various studies directed at improving quality of life and managing Gleevec-resistant patients. The data is very, very promising, reports Dr. Kolibaba. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power founder caught up with leading CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Watch as Dr. Kipps reviews data, including the use of ibrutinib (Imbruvica) in the frontline setting, the role of chemotherapy and an update on emerging therapies. Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Are clinical trials still a good idea for patients? Is there still a place for chemo? Who should get genetic testing and when should it be done? Dr. Nicole Lamanna, Associate Clinical Professor of Medicine at Columbia University Medical Center answers in-depth questions about CLL on location in Orlando, Florida at the 2015 American Society of Hematology (ASH). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Hematology (ASH) annual meeting, myeloma expert Dr. James Berenson joined Patient Power to discuss the recent wave of approvals for the treatment of multiple myeloma. Dr. Berenson speaks about the range of new therapies, discussing monoclonal antibodies, proteasome inhibitors and many others, including where each of these treatments fit into patient care. He also discusses potential issues with patient compliance, the cost of treatment and the path to cure. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

What is the REVEAL study, and why is it so important to polycythemia vera (PV) patients? On location at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Brady Stein from Robert H. Lurie Comprehensive Cancer Center discusses the demographics and benefits of the study. Dr. Stein is particularly hopeful with the new developments and sophisticated prognosis being applied to PV. You can learn more about the REVEAL study at revealpvstudy.com. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

CLL expert Dr. Jeff Sharman, on location at the ASH (American Society of Hematology) 2015 meeting, Dr. Jeff Sharman, shares the latest in CLL research news. Listen as Dr. Sharman explains in detail the expected outcomes of the RESONATE Phase III trial, as well as the ongoing research on ABT-199. When asked if he is hopeful, Dr. Sharman responds with an enthusiastic, Oh, gosh, yeah!…The statistics aren’t real anymore.CLL patients are living much more normal lives Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…

As part of Patient Power coverage from the 2015 American Society of Hematology (ASH), myeloma experts Dr. Noopur Raje, Dr. John Burke and Dr. Faith Davies, along with myeloma patient advocate Jack Aiello, gathered to discuss the latest news and research in multiple myeloma. The experts reviewed the recent approval of three new treatments, data presented on the power of combination therapy, important suggestions regarding prognosis and testing, and plenty of encouraging news based on presentations from the meeting. Each guest shares specific advice to myeloma patients to help them get the best care possible. Get email alerts | http://www.patientpower.info/alerts…

As part of our coverage of the 2015 American Society of Hematology annual meeting, MPN expert Dr. Richard Silver joined Patient Power to discuss interferon therapy for the treatment myeloproliferative neoplasms (MPNs), specifically myelofibrosis and polycythemia vera. Dr. Silver explains interferon, how it works, and the potential benefits of small doses of interferon therapy for MPNs. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Zeev Estrov, of MD Anderson Cancer Center, discusses fatigue in CLL patients including findings from ongoing research on JAK2 inhibitors and the encouraging news regarding reported symptom improvements. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam). The three validation studies included patients treated with Tam only (Stockholm), either anastrozole or Tam (ATAC), and Tam with a transition to letrozole (MA.17). For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

As part of our coverage of the 2015 American Society of Hematology annual meeting, myeloma expert Dr. Paul Richardson joined Patient Power to discuss this years approvals for the treatment of multiple myeloma, which includes seven total agents. Dr. Richardson reviews each of the treatments and shares how these new therapies work and how they impact multiple myeloma survival. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient Power founder Andrew Schorr led an expert panel as they reviewed CLL news from the 2015 American Society of Hematology (ASH) meeting in Orlando. Watch as Drs. John Gribben, Constantine Tam and William Wierda explore the full gamut of developing treatment approaches. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our coverage from the 2015 American Society of Hematology (ASH), a panel of MPN experts including Dr. Laura Michaelis, Dr. Ruben Mesa, Dr. Bart Scott and our own Andrew Schorr gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts discussed the changing treatment landscape in the field, their individualized approaches to treating MPN patients, and shared encouraging perspectives about current and future developing research. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Naval Daver of MD Anderson Cancer Center speaks candidly regarding the future of myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) research and treatment. Dr. Daver discusses the increasing value of genetic analysis as well as the push to find new drugs to defeat markers and mutations. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the European Cancer Congress (ECC) 2015, Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of IMvigor 210, a multicentre, phase 2 clinical trial that was designed to evaluate the efficacy and safety of atezolizumab, an anti-PD-L1 antibody, in patients with locally-advanced or metastatic urothelial carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rachael Crayton, Oncology Specialist Nurse from Central Manchester NHS Foundation Trust, Manchester, UK, discusses the key themes from a networking exercise with cancer survivorship programmes in the UK and USA that may be used to enhance these services for patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Patient Power founder Andrew Schorr talks with MPN expert Dr. Srdan Verstovsek to reflect on the final days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Dr. Verstovsek discuss the importance of a second opinion and specialized care. Learn why Dr. Verstovsek is excited about evolving research and the advances and hope of the near future. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Watch coverage from the 2015 American Society of Hematology (ASH) meeting with myeloma expert Dr. Robert Orlowski from MD Anderson Cancer Center as he joined Patient Power to answer questions from Patient Power community members. Dr. Orlowski answered a variety of questions and shared his thoughts on the latest news and research being shared at this years meeting. This program is sponsored by the Patient Empowerment Network through educational grants from Celgene, Novartis and Takeda. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Renowned CLL expert Dr. Jeff Sharman answered your questions LIVE, as we broadcasted from the 2015 American Society of Hematology (ASH) meeting. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From ASH 2015, patient advocates Andrew Schorr and Carol Preston are joined by myeloma specialist Dr. Gareth Morgan as they discuss the latest news. The panel discusses research highlights and the importance of being an informedand empoweredpatient. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Patient advocates and hosts Andrew Schorr and Carol Preston review the highlights from the first few days of the 2015 American Society of Hematology (ASH) meeting. Andrew and Carol are joined by Dr. Jennifer Brown, a leading CLL researcher, who shares her perspective on the role of genetics in treating CLL and her advice for getting the best care. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the RESONATE-2 trial, which studied the use of ibrutinib (Imbruvica) vs. chlorambucil in the frontline setting in patients over 65. Dr. Burger reviews the medications benefits in overall survival, progression free survival, and in response rates. Learn why Dr. Burger feels it is compelling to use ibrutinib more in the frontline setting for elderly patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the evidence requirements for the clinical development of prognostic and predictive genomic tests for individual risk stratification and adjuvant treatment selection in breast cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews This content is supported by Genomic Health, Inc.

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

The IMWG Conference Series “Making Sense of Treatment” 57th ASH Annual Meeting | Dec. 7, 2015 Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma

Saad Usmani, MD Levine Cancer Institute Charlotte, NC discusses the Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses how BCR Signaling Inhibitors Extremely Active and Generally Well Tolerated from ASH 2015

Brian T. Hill , MD, PhD Assistant Professor, Medicine, Case Western Reserve University School of Medicine (Cleveland Clinic) discusses the Practice Changing Drugs for CLL from ASH 2015

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses the fact that Precision Medicine Coming to Bone Marrow Transplant

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses Pre Transplant Depression Linked to Lower Overall Survival in Post Transplant Patients

Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses a Phase 3 Randomized Trial Support High Intensity Conditioning with Myeloablative Regimens in AML

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Ixazomib Has Not Shown The Cardiotoxicity of Injectable Proteasome Inhibitors

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about how Elotuzumab Shows Benefits When Treated Early in Multiple Myeloma

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how Daratumumab will Play Increasingly Important Role in Treating Multiple Myeloma According to ASH 2015 Data

Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about new ASH 2015 Data That Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the importance of the RESONATE-2 Trial Results Most Likely To Move Ibrutinib to Frontline in 2016

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses Precautions and Suggestions Regarding Management of Adverse Events of BCR Signaling Inhibitors

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses MD Andersons Real World Experience With BCR signaling Inhibitors in CLL

Nitin Jain, M.D. @CLLdoc Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the nd to Chemotherapy in CLL Most Likely as Targeted and Immunotherapy Move to Frontline

Chemotherapy-induced nausea and vomiting (CINV) remains a concern for many cancer patients. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton, UK, discusses current approaches for optimising the management of CINV. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ruth Hammond, Vascular Access and IV Nurse Practitioner, and Clinical Practice Educator at The Royal Marsden NHS Foundation Trust, London, UK, discusses the initial findings of an audit of the experiences of wearing medical alert bands in patients with suspected neutropenic sepsis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, explains the purpose of the UKONS, which includes promoting high standards in the nursing management and care of individuals affected by cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology Nursing Society (UKONS), which is run by cancer nurses for cancer nurses, and the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the impact of the Tenovus Cancer Care Sing with Us choirs, which are open to anyone affected by cancer, on those that participate. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, explains the potential benefits of lifestyle choices, including interventions on diet and physical activity, for cancer patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews the scientific and societal challenges of drug development for the treatment of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Entospletinib Why Its Different Than Fostamatinib

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology talks about how CLL has been Transformed in Last 5 Years and that the Hope is to Leave Chemotherapy Behind

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses ASH 2015 highlights as Bcl-2, BTK, and PI3 Inhibitors

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about how Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some Toxicity

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Ibrutinib or Idelalisib Preferred in Relapsed Patients Over Chemotherapy for CLL.

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses Chlorambucil v. Ibrutinib Shows Ibrutinib Powerful in Older Patients with CLL from ASH 2015

Susan M. OBrien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about the Adverse Events with Idelalisib + Rituximab May Be Autoimmune Related from ASH 2015

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses Imetelstat Pilot Study Data Released for MPN Patients

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PRM-151 Phase III Study Results in Myelofibrosis

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses how the COMFORT II Study Shows Ruxolitinib as a Very Durable Treatment for MPN from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Real World Experience with Approved BCR Signaling Inhibitors at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses R-CHOP With or Without Bortezomib Results at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses the New CAR T-Cell Studies Launching Now from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Natural Therapeutic Partners for BCR Signaling Inhibitors at ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Ibrutinib in Mantle Cell Lymphoma report from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses Atrial Fibrillation in Patients with CLL report from ASH 2015

Mitchell Smith, MD Director of the Lymphoid Malignancies at Cleveland Clinic Taussig Cancer Institute discusses ABT-199 Data Released at ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Real World Experience with Ibrutinib and Idelalisib from ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Novel Nucleoside Analog Ribose Sugar in AML at ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about Map Kinase Pathway P-38 in CLL

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses Choosing a BCR Signaling Inhibitor in CLL from ASH 2015

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope talks about ASH 2015 Highlights for Myeloma Treatments

Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma From ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Second Generation B2K Inhibitors Look Promising ACP-196 & BGB-3111 at ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib – Rituximab Combination for Relapsed CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Redistribution Lymphocytosis in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb and Ibrutinib in CLL at ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Combining Antibody TherapyWith BTK Inhibitor in Folicular Lymphoma at ASH 2015

Press brief by Mark C. Walters, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Walters provides an update on the Northstar study of subjects treated with the LentiGlobin BB305 Drug Product. Previously reported early results in subjects with ?-thalassemia major participating in the ongoing HGB-205 and HGB-204 (Northstar) studies suggest that transplantation with autologous CD34+ cells transduced with a replication-defective, self-inactivating LentiGlobin BB305 lentiviral vector containing an engineered ?A-T87Q?globin gene (LentiGlobin BB305 Drug Product) has a positive safety profile and leads to ?A-T87Qglobin production and can lead to transfusion independence.

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor T-Cells from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives an Update of Combining Immunotherapy with Targeted Therapies an Update from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives and update on Checkpoint Blockade from ASH 2015

Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update on BCR signaling inhibitors in CLL at ASH 2015

Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit of the modified UKONS telephone triage tool that has been implemented for the Acute Oncology Service at The Royal Marsden Hospital. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma. Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma.

Dr. Morie Gertz of the Mayo Clinic shares his overview of this year’s American Society of Hematology (ASH) meeting. He talks about Dr. Brian Durie’s discussion of three-drug treatment providing longer overall survival in newly diagnosed multiple myeloma patients versus two-drug treatment. He also discusses the recent advances in oral agents to treat multiple myeloma.

Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of Hematology’s (ASH) national conference this weekend. In this video, Dr. Lonial discusses the excitement at ASH about two-drug versus three-drug treatment approaches in newly diagnosed myeloma patients.

Dr. Kenneth Anderson of the Dana-Farber Cancer Institute and Vice President of the American Society for Hematology (ASH) shares about the exciting advances being discussed at the ASH annual conference this weekend in Orlando, Florida.

Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for newly diagnosed as well as relapsed/refractory multiple myeloma patients, as discussed this weekend at the American Society of Hematology (ASH) annual conference in Orlando, Florida.

Dr. Meletios Dimopoulus provides an update on the Eloquent-2 Trial: A Phase 3 Randomized, Open-Label Study of elotuzumab in Combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma. Dr. Meletios Dimopoulos National and Kapodistrian University of Athens School of Medicine Athens, Greece Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating natural killer cells and initiating antibody-dependent cell-mediated cytotoxicity targeted against myeloma cells, with minimal effect on normal tissues. In the 2-year progression-free survival (PFS)…

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK, reviews the advances in cancer immunotherapeutic approaches, highlighting the development of the anti-CTLA4 monoclonal antibody, ipilimumab, for the treatment of metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Saad Usmani reports on the clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis Centre University College London London, United Kingdom Survival of patients with cardiac AL amyloidosis remains poor due to high mortality in the first 6-12 months. Rapidly effective regimes such as CyBorD are unable to overcome poor prognosis in very advanced AL amyloidosis (Venner et al and Palladini et al Leukemia 2014). The median survival of moderately advanced AL is ~60% at 2 years with CyBorD (Palladini et al Blood 2015). Last year, we reported a small series suggesting that oral…

Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, discusses the overarching theme of patient safety and the subsidiary topic of haemato-oncology nursing at the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching, explains the concept of motivational interviewing as an approach for clinicians to communicate with patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Damian Green of Seattle Cancer Care Alliance presented at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discuses three new treatment options available for patients with multiple myeloma, and the role that clinical trials played in discovery of the new options.

Dr. Ryan Cassaday of Seattle Cancer Care Alliance presented a poster at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discusses how a treatment called hyperCVAD is making a difference for patients with ALL.

Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager at Myeloma UK, Edinburgh, UK, discusses Myeloma UKs Myeloma Academy, which is an interactive learning platform designed to provide continuing professional development opportunities for multiple myeloma healthcare professionals in order to support optimal patient care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust, Manchester, UK, discusses the recent progress, including the development of 5-HT3 and neurokinin-1 receptor antagonists as potential pharmacologic treatment options, in the management of chemotherapy-induced nausea and vomiting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the ManVan initiative, which is the first dedicated mobile support service for men with prostate, testicular or penile cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Somatic Profiles – NGS Testing

MPN expert Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center, shares his perspective on the future of research for myeloproliferative neoplasms, new medications and clinical trials. Dr. Komrokji explains how research, past and current, is pushing MPNs closer to becoming a chronic disease. He discusses both existing and new drug therapies and clarifies patient benefits when considering a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our Ask the Expert series, MPN expert Dr. Jamile Shammo of Rush University Medical Center responds to a Patient Power community members question, What do we know about ET and PV progression to myelofibrosis? Are there any ways progression can be slowed down? What research is being done in this area? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Winson Cheung – Best of Health Services / Survivorship – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Scott North – Best of Prostate – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Christian Kollmannsberger – Best of Non-Prostate – best of ASCO 2015 Vancouver

@OncEd Presents Dr. Stephen Chia – Best of Breast Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Michael Smylie – Best of Melanoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Howard Lim – Best of Non-Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Sharlene Gill – Best of Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Kerry Savage – Bet of Lymphoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Cheryl Ho – Best of Head and Neck – Best of ASCO 2015 Vancouver

@OncEd Presents Pancreatic Tumour Board – 2015

@OncEd Presents Dr. Allan Covens – BRCA Mutations in Ovarian Cancer – 2015

@OncEd Presents Dr. Scott Berry – First Line treatment of Unresectable Metastatic Colorectal Cancer – 2015

@OncEd Presents Dr. Natasha Leighl – Best of Lung Cancer – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Martina Trinkaus – Best of Hematology – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Eric Chen – Best of Head and Neck – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Kala Sridhar – Best of Non-Prostate – Best of ASCO 2015 Toronto

@OncEd Presents Dr. S̩bastien Hotte РBest of Prostate РBest of ASCO 2015 Toronto

@OncEd Presents Dr. Ron Burkes – Best of Colorectal – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Anthony Brade – Best of Radiation Oncology – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Yoo-Joung Ko – Best of Non-Colorectal – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Marcus Butler – Best of Melanoma – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Philippe Bedard – Best of Breast Cancer – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Benoit Samson – Best of Survivorship – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Jamil Asselah – Best of Breast Cancer – Best of ASCO 2015 Montreal

@OncEd Presents Dr. F̩lix Couture РBest of Colorectal РBest of ASCO 2015 Montreal

@OncEd Presents Dr. John Storring – Best of Hematology – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Benoit Samson – Best of Lung Cancer – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Fr̩d̩ric Lemay РBest of GI Cancers РBest of ASCO 2015 Montreal

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses a doctoral study that was designed to evaluate the lived experience of men who have survived at least five years after a diagnosis of prostate cancer received at or after the age of 65 years. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK, discusses the development of a nurse-led, pre-treatment, telephone assessment service to address waiting times for patients receiving ipilimumab for metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager, Myeloma UK, Edinburgh, UK, discusses the role of nurses for improving the quality of life and survival of patients with multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr.Fran̤ois Patenaude РBest of Renal Cancer РBest of ASCO 2015 Montreal

@OncEd Presents Dr.Cristiano Ferrario – Best of Prostate – Best of ASCO 2015 Montreal

@OncEdPresents Dr. David Hogg – Best of Melanoma – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Jennifer Knox – Gastric, Biliary & Hepatocellular Cancers – GUGI 2015

@OncEd Presents Dr. Jean-Bernard Durand – Assessing the Impact Cardio-Toxicities Have on Patients When Continuing Chemotherapeutic Agents

@OncEd Presents Dr. Scot Dowden – Pancreatic Cancer – GUGI 2015

@OncEd Presents Dr. Nathaniel Bouganim – Best of Head and Neck – Best of ASCO 2015 Montreal

@OncEd Presents Dr. Scott Berry – Colorectal Cancers – GUGI 2015

@OncEd Presents Dr. Eric Winquist – Bladder and Testis Cancer – GUGI 2015

@OncEd Presents Dr. Georg Bjarnason – Renal Cell Cancer – GUGI 2015

@OncEd Presents Dr. S̩bastien Hotte РCastrate Refractory Disease РGUGI 2015

@OncEd Presents Dr. Andrew Loblaw – Early Disease – GUGI 2015

@OncEd Presents Dr. Neil Fleshner – Hormone Sensitive Disease – GUGI 2015

@OncEd Presents Dr. Daniel Renouf – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 3 – Best of Oncology West 2015

@OncEd Presents Dr. Sharlene Gill – Individualized treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 1 – Best of Oncology West 2015

@OncEd Presents Dr. Winson Cheung – Individualized Treatment in Advanced Pancreatic Cancer: A Case-Based Discussion – Case 2 – Best of Oncology West 2015

@OncEd Presents Dr. Cynthia Wu – Breakfast Symposium: Blood Clots in Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Ralph Wong – Best of GI Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Ralph Wong – Best of GI-Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Joanna Vergidis – Best of GU Cancers – Best of Oncology West 2015

@OncEd Presents Dr. Christine Simmons – Best of Breast Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Kerry Savage – Best of Lymphoma- Best of Oncology West 2015

@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Jonathan Loree – Impact of Post-Operative Adjuvant Fluoropyrimidine Chemotherapy Following Pre-Operative Short Course Radiotherapy in Stage II Rectal Cancer – Best f Oncology West 2015

@OncEd Presents Dr. Richard Lee-Ying – Utility of Surveillance Following Curative Intent Resection of Metastases – Best of Oncology West 2015

@OncEd Presents Dr.Cheryl Ho – Best of Head & Neck Cancer- Best of Oncology West 2015

@OncEd Presents Dr.Sharlene Gill – Best of GI-Non-Colorectal Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Susan Ellard – Gynecological Cancer Updates – Best of Oncology West 2015

@OncEd Presents Dr. Jay Easaw – Breakfast Symposium: Blood Clots in Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Wendie Den Brok – Survival of Metastatic HR Positive/HER2 Negative, Triple Negative and HER2 Positive Breast Cancer – Best of Oncology West 2015

@OncEd Presents Dr. Stephen Chia – Treating Advanced Breast Cancer in the Genomic Era – Best of Oncology West 2015

@OncEd Presents Dr. Philip Halloran – Identifying T Cell-Mediated Inflammation in Tissue by Molecular Phenotyping: Lessons from Kidney Transplantation – Canadian Melanoma Conference 2015

@OncEd Presents Dr. David Hogg & Dr. Xinni Song – Addressing Key Questions in immune-Oncology – Canadian Melanoma Conference 2015

@OncEd Presents Dr. David Zloty – Mohs Surgery for Melanoma and Merkel – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Heidi Wat – A Seven-Year analysis of Mitotic Rate & Sentinel Lymph Node Biopsy Status in Patients with Melanoma in Alberta From 2007-2013 – Canadian Melanoma Conference 2015

@OncEd Presents Dr. Chlo̩ Ward РThe Rate of Missed Melanoma in Sentinel Node Negative Patients: The Ottawa Experience РCanadian Melanoma Conference 2015